Current Report Filing (8-k)
January 10 2020 - 3:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): January 7,
2020
AMERICAN BIO MEDICA CORPORATION
(Exact
name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State or other
jurisdiction of incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification Number)
|
122 Smith Road,
Kinderhook, NY
|
12106
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
|
ABMC
|
Over-the-counter-Pink
Sheets
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On
January 7, 2020, Diane Generous informed the Board of her decision
to resign from her position on the Company’s Board of
Directors. Mrs. Generous provided the Company with her resignation
in writing and her letter did not contain any statements describing
disagreements with the Company related to its operations, policies
or practices, not did any such disagreement lead to her
resignation. Mrs. Generous has served on the Board of Directors
since December 2014. She has served as the Chairman of the
Nominating Committee and as a member of the Audit and Compensation
Committees.
The
remaining members of the Board of Directors, (Chairman Chaim Davis,
Jean Neff, Peter Jerome and Company Chief Executive
Officer/Principal Financial Officer Melissa Waterhouse) are
considering whether to fill the vacant board seat (whose term is
set to expire in June 2020) or to fix the number of board seats to
four (4) as allowed under the Company’s Amended and Restated
Bylaws by a majority of the Board of Directors.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
Date:
January 10, 2020
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
Chief
Executive Officer (Principal Executive Officer)
Principal Financial
Officer
|
|
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Aug 2024 to Sep 2024
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Sep 2023 to Sep 2024